Anbio Biotechnology Announces Pricing of Initial Public Offering
The Company expects to receive aggregate gross proceeds of US$8 million from the Offering, before deducting underwriting discounts and other related expenses. The Offering is expected to close on or ...
How Biotech Can Succeed Outside the Hubs
Though most biopharma investment is in two states, follow this model to bring the research—and investments—elsewhere.
Biogen, Stoke Therapeutics announce zorevunersen commercialization agreement
Biogen (BIIB) and Stoke Therapeutics (STOK) announced a collaboration for the development and commercialization of zorevunersen, a potential ...